Guard Therapeutics today announced that it has reached the important milestone of enrolling 25% of its target in the phase 2b POINTER study. This trial is evaluating the kidney-protective effects of the investigational drug RMC-035 in patients undergoing open-heart surgery. The next major milestone will be the result of the first of two independent, blinded safety analyses, expected in the first quarter of 2025.
Guard Therapeutics International AB (publ) today announced that a Nomination Committee has been appointed in accordance with previous AGM resolutions.
Guard Therapeutics today announced that the first patient in Europe was dosed in the phase 2b POINTER study with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
The board of directors of Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announces the outcome in the rights issue of shares (repair issue) announced on 27 August 2024 (the “Rights Issue”). The outcome shows that, in total, 227,922 shares were subscribed for by exercise of subscription rights, corresponding to approximately 8.5 per cent of the Rights Issue, and 10,968 shares were subscribed for without subscription rights, corresponding to approximately 0.4 per cent of the Rights Issue. The Rights Issue was thus subscribed to a total of approximately 8.9 per cent, and through the Rights Issue, the Company will receive approximately SEK 7.2 million before transaction costs.
Guard Therapeutics today announced that the renowned scientific journal eClinicalMedicine, part of Lancet Discovery Science, has published an article describing the main findings from the company's phase 2 clinical study AKITA with the drug candidate RMC-035, which is being evaluated for the treatment of kidney injury associated with open-heart surgery. The results form the basis for the continued clinical development program with RMC-035 and the design of the recently initiated phase 2b POINTER study.
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) has, due to the Company’s upcoming rights issue of shares, that was announced on 27 August 2024 (the “Rights Issue”), prepared an EU Growth Prospectus (the “Prospectus”), which today has been approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
The board of directors of Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”), in accordance with the announcement of a non-guaranteed rights issue (repair issue) which was communicated through the Company’s press release on 17 June 2024, has today resolved to carry out a new issue of shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”) based on the authorization granted by the extraordinary general meeting on 3 July 2024. The Rights Issue is mainly carried out to compensate the shareholders that did not participate in the directed share issue that the board of directors of the Company resolved upon on 17 June 2024 (the “Directed Share Issue”) by offering the Company’s shareholders the opportunity to defend their share ownership on the same terms as in the Directed Share Issue.
Guard Therapeutics announced today that, through the European application procedure, the company has received authorization from regulatory authorities and ethics committees in Spain, Germany, and the Czech Republic to include patients in the clinical Phase 2b study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.